Pharmafile Logo
Pharmafocus logo
Advanced Search

lynparza

Showing 5 posts of 35 posts found.

NICE

NICE demands more evidence of Lynparza benefits

August 6, 2015
Sales and Marketing AstraZeneca, NICE, lynparza, ovarian cancer

AstraZeneca must provide a “robust estimate of the cost effectiveness” of its ovarian cancer treatment Lynparza, or risk being rejected …

News

NICE Lynparza rejection labelled ‘hard to understand’

June 2, 2015
Sales and Marketing AstraZeneca, NICE, lynparza, olaparib

AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …

News
AZ image

AstraZeneca drops CDF application

January 12, 2015
Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib

AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …

News
Astrazeneca image

AstraZeneca ovarian cancer drug approved in Europe

December 18, 2014
Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian

The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …

News
AZ image

AZ oncology drug a ‘Phoenix from the flames’

October 27, 2014
Sales and Marketing AstraZeneca, CHMP, EC, lynparza, olaparib, oncology

As the possibility of a deal with Pfizer fades, AstraZeneca is continuing its argument for independence as a key cancer …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025